

Help your patients afford Cromolyn Sodium. A provider's guide to savings programs, coupons, generics, and cost conversations that improve adherence.
If you prescribe Cromolyn Sodium for mastocytosis or mast cell activation syndrome (MCAS), you've likely heard from patients struggling to afford it. With cash prices ranging from $130 to over $400 per month for the oral solution — and an ongoing shortage driving prices higher at some pharmacies — cost is a significant adherence barrier.
This guide provides a practical framework for helping your patients access Cromolyn at a lower cost, including manufacturer programs, coupon cards, compounding options, and how to build cost conversations into your workflow.
Understanding the cost landscape helps you anticipate patient concerns and offer solutions proactively.
Coverage for Cromolyn varies significantly across payers:
When prior authorization is required, providing clear documentation of the diagnosis (systemic mastocytosis, elevated tryptase levels, or documented MCAS criteria) and failed trials of alternative therapies significantly improves approval rates.
Viatris, the parent company of Meda Pharmaceuticals (maker of Gastrocrom), may offer a patient assistance program for qualifying low-income patients. Eligibility typically requires:
Contact Viatris Patient Assistance at their website or have your office staff reach out directly. Processing can take 4–6 weeks, so initiate early.
Prescription Hope is a patient assistance organization that offers Gastrocrom for $70 per month through partnerships with pharmaceutical manufacturers. This program is available to patients regardless of income, insurance status, or age. Enrollment is done online and typically processed within 1–2 weeks.
This is one of the most straightforward cost-reduction options and worth mentioning to every patient who expresses cost concerns.
For patients paying out of pocket or facing high copays, prescription discount cards can provide meaningful savings on generic Cromolyn Sodium.
A practical workflow: direct patients to compare prices on GoodRx and SingleCare before filling, and remind them that prices can vary by $50–$100+ between pharmacies for the same medication.
Generic Cromolyn Sodium oral solution is available from manufacturers including Micro Labs, Rising Pharmaceuticals, and Omnivium Pharmaceuticals. Generics are therapeutically equivalent and significantly cheaper than brand-name Gastrocrom. Always prescribe generically unless there's a clinical reason for the brand.
When commercial Cromolyn oral solution is unavailable due to the ongoing shortage, compounding pharmacies can prepare Cromolyn in oral capsule form. Key considerations:
If cost or availability makes Cromolyn untenable, consider discussing therapeutic alternatives with your patients:
Document the clinical rationale for any therapeutic substitution, particularly if the switch is driven by cost or availability rather than clinical preference.
Cost discussions don't have to be awkward or time-consuming. Here are practical ways to integrate them:
Cromolyn Sodium is an essential medication for many patients with mastocytosis and MCAS, but cost and availability can undermine even the best clinical outcomes. By proactively addressing cost at the point of prescribing, connecting patients with savings programs, and having a plan for when the commercial product is unavailable, you can help your patients stay on therapy.
For real-time Cromolyn availability and provider tools, visit Medfinder for Providers. For a patient-facing guide you can share, see our post on how to save money on Cromolyn.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.